JP2022533705A5 - - Google Patents
Info
- Publication number
- JP2022533705A5 JP2022533705A5 JP2021569042A JP2021569042A JP2022533705A5 JP 2022533705 A5 JP2022533705 A5 JP 2022533705A5 JP 2021569042 A JP2021569042 A JP 2021569042A JP 2021569042 A JP2021569042 A JP 2021569042A JP 2022533705 A5 JP2022533705 A5 JP 2022533705A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complement
- neuropathy
- antigen
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024220534A JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907153.9 | 2019-05-21 | ||
| GB1907153.9A GB2584105B (en) | 2019-05-21 | 2019-05-21 | Methods of treating neuropathy |
| PCT/EP2020/064234 WO2020234432A1 (en) | 2019-05-21 | 2020-05-21 | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024220534A Division JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Division JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533705A JP2022533705A (ja) | 2022-07-25 |
| JP2022533705A5 true JP2022533705A5 (enExample) | 2023-05-31 |
| JP7607590B2 JP7607590B2 (ja) | 2024-12-27 |
Family
ID=67385155
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569042A Active JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20250066460A1 (enExample) |
| EP (2) | EP3972643B1 (enExample) |
| JP (3) | JP7607590B2 (enExample) |
| KR (1) | KR20220010505A (enExample) |
| CN (2) | CN118021970A (enExample) |
| AU (1) | AU2020279543A1 (enExample) |
| BR (1) | BR112021023198A2 (enExample) |
| CA (1) | CA3138401A1 (enExample) |
| DK (1) | DK3972643T3 (enExample) |
| EA (1) | EA202193189A1 (enExample) |
| ES (1) | ES3035736T3 (enExample) |
| FI (1) | FI3972643T3 (enExample) |
| GB (1) | GB2584105B (enExample) |
| HU (1) | HUE072743T2 (enExample) |
| IL (1) | IL288010A (enExample) |
| LT (1) | LT3972643T (enExample) |
| MA (1) | MA71752A (enExample) |
| MX (2) | MX2021014170A (enExample) |
| PL (1) | PL3972643T3 (enExample) |
| PT (1) | PT3972643T (enExample) |
| SG (1) | SG11202112232YA (enExample) |
| WO (1) | WO2020234432A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3893924T (lt) * | 2018-12-13 | 2024-10-10 | argenx BV | Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai |
| CN117597353A (zh) * | 2021-03-18 | 2024-02-23 | 艾菲洛之克公司 | 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途 |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| US20240166692A1 (en) * | 2021-03-18 | 2024-05-23 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| WO2022198108A1 (en) * | 2021-03-18 | 2022-09-22 | Affilogic | Polypeptides for complement inhibition |
| US20250074973A1 (en) * | 2021-12-30 | 2025-03-06 | Annexon, Inc. | Compositions and methods for treating huntington’s disease |
| CA3259060A1 (en) * | 2022-07-14 | 2024-01-18 | argenx BV | DOSAGE REGIMEN FOR THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY (MMN) |
| KR20250158059A (ko) * | 2023-03-07 | 2025-11-05 | 더 클리브랜드 클리닉 파운데이션 | 인간 보체 성분 2 결합 분자 |
| WO2025146509A1 (en) * | 2024-01-05 | 2025-07-10 | argenx BV | Methods of treating multifocal motor neuropathy (mmn) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| KR101503540B1 (ko) * | 2006-09-05 | 2015-03-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항체 매개된 신경병증의 치료를 위한 방법과 조성물 |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| SI3028716T1 (sl) * | 2006-10-10 | 2021-01-29 | Regenesance B.V. | Komplementarna inhibicija za izboljšano regeneracijo živcev |
| US9447176B2 (en) * | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| CA2847862C (en) * | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| CN102949719A (zh) * | 2012-04-28 | 2013-03-06 | 上海市徐汇区中心医院 | 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1 |
| WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| WO2014186622A2 (en) * | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| US9944717B2 (en) * | 2013-05-23 | 2018-04-17 | Broteio Pharma B.V. | Binding molecules that bind human complement factor C2 and uses thereof |
| CA2931090A1 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| ES3013108T3 (en) * | 2014-11-05 | 2025-04-11 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
| US11091591B2 (en) * | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| CN115260310B (zh) * | 2015-11-24 | 2025-02-25 | 安尼艾克松股份有限公司 | 抗补体因子c1q的fab片段及其应用 |
| EP3454902A4 (en) * | 2016-05-10 | 2019-10-09 | Annexon, Inc. | ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF |
| BR112019018950A2 (pt) * | 2017-03-14 | 2020-04-22 | Bioverativ Usa Inc. | métodos para tratamento de doenças e distúrbios mediados por complemento |
| US11866701B2 (en) * | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| LT3893924T (lt) * | 2018-12-13 | 2024-10-10 | argenx BV | Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai |
-
2019
- 2019-05-21 GB GB1907153.9A patent/GB2584105B/en active Active
-
2020
- 2020-05-21 LT LTEPPCT/EP2020/064234T patent/LT3972643T/lt unknown
- 2020-05-21 US US17/608,637 patent/US20250066460A1/en active Pending
- 2020-05-21 WO PCT/EP2020/064234 patent/WO2020234432A1/en not_active Ceased
- 2020-05-21 CN CN202410047987.6A patent/CN118021970A/zh active Pending
- 2020-05-21 CA CA3138401A patent/CA3138401A1/en active Pending
- 2020-05-21 JP JP2021569042A patent/JP7607590B2/ja active Active
- 2020-05-21 SG SG11202112232YA patent/SG11202112232YA/en unknown
- 2020-05-21 BR BR112021023198A patent/BR112021023198A2/pt unknown
- 2020-05-21 MX MX2021014170A patent/MX2021014170A/es unknown
- 2020-05-21 ES ES20729653T patent/ES3035736T3/es active Active
- 2020-05-21 KR KR1020217039139A patent/KR20220010505A/ko active Pending
- 2020-05-21 DK DK20729653.4T patent/DK3972643T3/da active
- 2020-05-21 EA EA202193189A patent/EA202193189A1/ru unknown
- 2020-05-21 EP EP20729653.4A patent/EP3972643B1/en active Active
- 2020-05-21 FI FIEP20729653.4T patent/FI3972643T3/fi active
- 2020-05-21 PT PT207296534T patent/PT3972643T/pt unknown
- 2020-05-21 CN CN202080037596.6A patent/CN114269382B/zh active Active
- 2020-05-21 EP EP25159620.1A patent/EP4570316A3/en active Pending
- 2020-05-21 HU HUE20729653A patent/HUE072743T2/hu unknown
- 2020-05-21 PL PL20729653.4T patent/PL3972643T3/pl unknown
- 2020-05-21 AU AU2020279543A patent/AU2020279543A1/en active Pending
- 2020-05-21 MA MA71752A patent/MA71752A/fr unknown
-
2021
- 2021-11-11 IL IL288010A patent/IL288010A/en unknown
- 2021-11-18 MX MX2025014486A patent/MX2025014486A/es unknown
-
2024
- 2024-12-17 JP JP2024220534A patent/JP2025038109A/ja active Pending
- 2024-12-18 JP JP2024221343A patent/JP2025041724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11167038B2 (en) | Methods for improving safety of blood-brain barrier transport | |
| JP5695317B2 (ja) | 抗体媒介性ニューロパシーを処置するための方法および組成物 | |
| JP7071349B2 (ja) | ピログルタメートアミロイド－βに対する抗体及びその使用 | |
| KR101999872B1 (ko) | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 | |
| CN107074965B (zh) | 特异性结合微管相关蛋白tau的抗体和抗原结合片段 | |
| ES2756649T3 (es) | Anticuerpos contra tau y usos de los mismos | |
| JP2020007318A5 (enExample) | ||
| JP2021191267A5 (enExample) | ||
| FI3972643T3 (fi) | Komplementtijärjestelmän antagonisteja käytettäväksi paraproteinemisten neuropatioiden hoitomenetelmissä | |
| AU2011336716A1 (en) | Low affinity blood brain barrier receptor antibodies and uses therefor | |
| CN109562167A (zh) | 联合治疗 | |
| WO2021212049A2 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| CN102037018A (zh) | 识别结合了抗原的抗体与没有结合抗原的抗体的结构变化的抗体及其获得方法 | |
| CN107001452A (zh) | 用于治疗癌症的抗ck8抗体 | |
| JP2023537078A5 (enExample) | ||
| CN114594272B (zh) | 用于检测β-淀粉样蛋白的产品和方法 | |
| CN114605532B (zh) | 抗β-淀粉样蛋白抗体及其用途 | |
| JP5683466B2 (ja) | 抗ｐｓｋ抗体 | |
| CN119546631A (zh) | 用于治疗支气管扩张的抗PcrV和Psl双特异性抗体 | |
| NZ781789B2 (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| CN114591429B (zh) | 结合β-淀粉样蛋白的抗体及其用途 | |
| HK40063067B (zh) | 用於治疗副蛋白血症性神经病的方法的补体系统的拮抗剂 | |
| HK1191341B (zh) | 低亲和力血脑屏障受体抗体及其用途 | |
| HK1259793B (zh) | 用於提高血脑屏障转运的安全性的方法 |